MedTrace Logo

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

NCT05027425 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.

Conditions

Interventions

PROCEDURE

Liver Transplant

minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.

DRUG

Durvalumab

1500 mg IV, Q4W

DRUG

Tremelimumab

300 mg IV, 1 dose on day 1 of only the first cycle

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Davendra Sohal, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-07
Primary Completion
2024-11-07
Completion
2024-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05027425 on ClinicalTrials.gov